Public Employees Retirement System of Ohio Takes Position in Tyra Biosciences, Inc. $TYRA

Public Employees Retirement System of Ohio acquired a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 18,512 shares of the company’s stock, valued at approximately $177,000.

A number of other hedge funds have also recently modified their holdings of TYRA. Vestal Point Capital LP grew its position in shares of Tyra Biosciences by 190.9% during the 1st quarter. Vestal Point Capital LP now owns 2,879,829 shares of the company’s stock valued at $26,782,000 after acquiring an additional 1,889,829 shares during the period. Woodline Partners LP bought a new stake in shares of Tyra Biosciences during the 1st quarter valued at $931,000. Millennium Management LLC grew its position in shares of Tyra Biosciences by 28.2% during the 1st quarter. Millennium Management LLC now owns 404,165 shares of the company’s stock valued at $3,759,000 after acquiring an additional 89,024 shares during the period. Walleye Capital LLC grew its position in shares of Tyra Biosciences by 123.5% during the 1st quarter. Walleye Capital LLC now owns 140,742 shares of the company’s stock valued at $1,309,000 after acquiring an additional 77,762 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its position in shares of Tyra Biosciences by 23.6% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 301,801 shares of the company’s stock valued at $2,807,000 after acquiring an additional 57,556 shares during the period. Institutional investors own 84.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Wall Street Zen raised shares of Tyra Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. Oppenheimer reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Tyra Biosciences in a report on Wednesday, September 10th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Tyra Biosciences in a report on Friday, August 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a report on Saturday, September 27th. Finally, Raymond James Financial assumed coverage on shares of Tyra Biosciences in a report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $35.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Tyra Biosciences has an average rating of “Moderate Buy” and an average price target of $31.86.

Tyra Biosciences Stock Down 1.7%

Shares of TYRA stock opened at $13.43 on Tuesday. The stock has a market cap of $715.82 million, a P/E ratio of -7.54 and a beta of 1.11. Tyra Biosciences, Inc. has a 52 week low of $6.42 and a 52 week high of $29.60. The company’s fifty day simple moving average is $11.97 and its two-hundred day simple moving average is $10.48.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.06. On average, analysts anticipate that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.